AstraZeneca has seen more than £20 billion wiped off its stock market value after being hit by a setback in a trial for a new drug to treat heart disease.
The FTSE 100 firm’s stock slumped by as much as 11% on Thursday morning after the pharmaceutical giant found the Wainua drug – which is being jointly developed with US firm Ionis – failed to meet a goal to reduce deaths related to heart disease when added to the normal standard of care given to patients.
